
CONTENTS

PART **1**

ESSENTIALS OF MODERN ONCOLOGIC SCIENCE

1

Essentials of Molecular Biology: Basic Principles **3**

LANCE A. LIOTTA
EDISON T. LIU

Storage and Transmission of Genetic Information 3
Reading the Genetic Code and Production of Encoded Proteins 7
Protein Structure and Function 8
Subcellular Molecular Structure 9
Different Pathways to Cancer 12
Suggested Readings 15

2

Essentials of Molecular Biology: Genomics and Cancer. **17**

LANCE A. LIOTTA
EDISON T. LIU

Understanding Cancer at the Molecular Level: The New Frontier 17
Genetic Mechanisms of Cancer Progression: Cancer Is a Genetic Disease 17
Cancer Genes: Models of Action 18
Molecular Profiling: Prognosis and Treatment Tailored
to the Individual Patient 20

Postgenome Challenge for Molecular Medicine 21

cDNA Microarrays Are a New Tool to Analyze Gene Expression Patterns
in Human Cancer 22

Technology for Tissue Microdissection Brings Molecular Analysis
to the Tissue Cell Level 24

Tumor Tissue Arrays 25

Beyond Functional Genomics to Cancer Proteomics 25

3

Essentials of Signal Transduction **31**

CHRISTOPHER L. CARPENTER
LEWIS C. CANTLEY

The Sensory Machinery: Ligands and Receptors 31

Propagation of Signals to the Cell Interior 34

Efficiency and Specificity: Formation of Multiprotein Signaling Complexes 38

Regulation of Protein Levels: Transcription, Translation,
and Proteolysis 39

4

Essentials of Immunology **43**

NICHOLAS P. RESTIFO
JOHN R. WUNDERLICH

T Cells and Cellular Immunity 43

Antigen Presentation to T Cells 44

Specialized Antigen-Presenting Cells 50

T-Cell Recognition of Antigens 51

T-Cell Maturation 53

Activation of Mature T Cells 55

States of Mature T Cells 59

Functions of Mature T Cells 60

Cytotoxic Effector Cell Mechanisms 61

B Cells and Humoral Immunity 64

Summary 67

PART 2

PRINCIPLES OF ONCOLOGY

5

Molecular Biology of Cancer: Cytogenetics **77**

MAZIN B. QUMSIYEH
PEINING LI

History of Cancer Cytogenetics 77

Chromosome Structure and Function 77

Cytogenetic Methods	79
International System of Cytogenetic Nomenclature	82
Mechanisms and Implications of Chromosomal Abnormalities in Cancer	82
Cautions to Exercise in Interpreting Chromosomal Abnormalities Seen in Cancer Studies	86
Clonal Evolution and Chromosome Evolution	87
Constitutional Chromosomal Abnormalities Predisposing to Cancer Development	88
Data Mining in Cancer Cytogenetics	89
Glossary	89

6

<i>Molecular Biology of Cancer: The Cell Cycle</i>	91
--	-----------

MICHAEL B. KASTAN
STEPHEN X. SKAPEK

Mechanics of the Cell Division Cycle	91
Control of the Cell Division Cycle	99
Implications for Cancer	102

7

<i>Molecular Biology of Cancer: Apoptosis</i>	111
---	------------

STANLEY J. KORSMEYER
SANDRA S. ZINKEL

Apoptosis	111
Genetics of Cell Death	112
Death Receptors	113
Caspases	113
The Bcl-2 Family	114
Bcl-2 Family Members Play Critical Roles in Tissue Homeostasis	117
Role of Mitochondria	118
Cell Proliferation and Apoptosis	118
Possibilities for Therapeutic Intervention	118
Conclusions	119

8

<i>Molecular Biology of Cancer: Invasion and Metastases</i>	123
---	------------

WILLIAM G. STETLER-STEVENSON
DAVID E. KLEINER, JR.

The Metastatic Cascade	123
Oncogenesis: Metastasis and Tumorigenesis Are under Separate Genetic Control	125
Angiogenesis: Balance of Positive and Negative Effectors	126
Tumor Heterogeneity and Clonal Dominance	126
Defining the Invasive Phenotype	126
Cell-Cell Adhesion Suppresses or Facilitates Metastasis Formation	127
Cell-Extracellular Matrix Interactions in Tumor Progression	129
Intravasation, Extravasation, and Orthotopic Effect	134

9

Biology of Cancer: Angiogenesis 137

ISAIAH J. FIDLER
ROBERT S. KERBEL
LEE M. ELLIS

Neoplastic Angiogenesis: The Balance of Proangiogenic and Antiangiogenic Molecules	137
Lymphoid Cell-Mediated Angiogenesis	140
Regulation of Angiogenic Factor Expression in Tumors	140
Endogenous Inhibitors of Angiogenesis	140
Clinical Utility of Angiogenesis	141
Antiangiogenic Therapy: Issues and Expectations	143
Antiangiogenic Therapy as a Component of Other Antineoplastic Regimens	144
Conclusions	144

10

Etiology of Cancer: Viruses 149

SECTION 1 *RNA Viruses* 149

ERIC M. POESCHLA
GARY L. BUCHSCHACHER, JR.
FLOSSIE WONG-STAAAL

Retroviral Genetics: Selective Access to the Growth Control Genes of the Cell	149
Mechanisms of Retroviral Oncogenesis	150
Human T-Cell Leukemia Virus Type I	152
Human T-Cell Leukemia Virus Type II	154
Human Immunodeficiency Virus	154
Hepatitis C Virus	155

SECTION 2 *DNA Viruses* 158

PETER M. HOWLEY
DON GANEM
ELLIOTT KIEFF

Hepadnaviruses and Hepatocellular Carcinoma	158
Papillomaviruses and Human Cancer	161
Epstein-Barr Virus	168
Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus-8)	171

11

Etiology of Cancer: Chemical Factors 179

STUART H. YUSPA
PETER G. SHIELDS

The Nature of Chemical Carcinogens: Chemistry and Metabolism	180
Animal Model Systems and Multistage Carcinogenesis	181
Protection against Chemical Carcinogens: DNA Repair, Tumor Suppressor Genes, and Transforming Growth Factor- β	184
Genetic Susceptibility to Chemical Carcinogenesis in Experimental Models	184

Determination of Chemical Carcinogens for Humans and Population-Based Risk Assessment	185
Molecular Epidemiology of Cancer Risk from Chemicals	186
Mutational Spectrum of Human Cancers	190
Tobacco Smoking and Cancer Risk	190

12

<i>Etiology of Cancer: Physical Factors</i>	195
ROBERT L. ULLRICH	
Interactions of Radiation with Cells and Tissues	195
Ionizing Radiation and Cancer	197
Ultraviolet Light	202
Asbestos	204

13

<i>Etiology of Cancer: Cancer Genetics</i>	207
ALLEN E. BALE	
SUZANNE J. BROWN	
Cancer as a Genetic Disease	207
Mechanisms of Cancer Predisposition	207
Gatekeepers, Caretakers, and Landscapers	211
Clinical Characteristics of Cancer Families	211
Multisystem Genetic Syndromes with a High Risk of Cancer	212
Nonsyndromic Hereditary Cancer	215

14

<i>Epidemiology of Cancer</i>	219
SECTION 1 <i>Epidemiologic Methods</i>	219
MARGARET A. TUCKER	
Observational Studies	219
Descriptive Studies	221
Analytic Studies	221
Intervention Studies	226
Future Directions	227
SECTION 2 <i>Descriptive Epidemiology: Cancer Statistics</i>	228
PHILIP COLE	
BRAD RODU	
Descriptive Epidemiology	228
Perspectives	238
SECTION 3 <i>Analytic Epidemiology: Cancer Causes</i>	241
PHILIP COLE	
BRAD RODU	
Evaluating Carcinogenicity	241
Causes of Cancer	242
Perspectives	249

15

Principles of Cancer Management: Surgical Oncology 253

STEVEN A. ROSENBERG

Historical Perspective 253

Anesthesia for Oncologic Surgery 254

Determination of Operative Risk 256

Roles for Surgery 259

The Surgical Oncologist 262

16

Principles of Cancer Management: Radiation Therapy 265

SAMUEL HELLMAN

Physical Considerations 265

Biologic Considerations 270

Clinical Considerations 282

17

Principles of Cancer Management: Chemotherapy 289

EDWARD CHU

VINCENT T. DEVITA, JR.

History 289

Chemotherapy as Part of the Initial Treatment of Cancer 290

Clinical End Points in Evaluating Response to Chemotherapy 291

Principles Governing the Use of Combination Chemotherapy 292

Effect of the Biology of Tumor Growth on Response to Chemotherapy 294

Apoptosis, Cell-Cycle Control, and Resistance to Chemotherapy 295

Concept of Dose Intensity 300

In Vitro Drug-Response Assays 302

18

Principles of Cancer Management: Biologic Therapy 307

STEVEN A. ROSENBERG

Basic Principles of Tumor Immunology 307

Cells of the Immune System 308

Immune Effector Mechanisms Resulting in Cell Destruction 308

Cytokines 308

Tumor Antigens 320

Immunotherapy 324

Interferons 326

19

Pharmacology of Cancer Chemotherapy 335

SECTION 1 *Pharmacokinetics and Pharmacodynamics 335*

MARK J. RATAIN

Pharmacokinetics: Fundamental Principles 335

Pharmacokinetics: What's Important to the Clinician? 338

Basic Methodology of Pharmacokinetic Studies 339

Pharmacodynamics 340

**Rational Use of Pharmacokinetic and Pharmacodynamic Data
in Clinical Oncology 340**

SECTION 2 *Cancer Drug Development 345*

Section 2.1 Identification and Screening of New Agents 345

EDWARD CHU

MICHAEL R. GREVER

BRUCE A. CHABNER

Drug Discovery 345

Drug Development 352

Conclusion 354

Section 2.2 Combinatorial Chemistry 356

DAVID J. AUSTIN

Principles of Combinatorial Chemistry 356

The History of Combinatorial Chemistry 357

The Practice of Combinatorial Chemistry 359

Combinatorial Chemistry in Pharmaceutical Drug Development 360

The Future of Chemical Diversity in Drug Development 362

SECTION 3 *Antitumor Alkylating Agents 363*

OLIVER MICHAEL COLVIN

History of the Alkylating Agents 363

Chemistry and Cytotoxicity of Alkylating Agents 363

Classes of Alkylating Agents and Their Properties 363

Mechanisms of Toxicity and Drug Resistance 369

Common Toxicities 371

SECTION 4 *Cisplatin and Its Analogues 376*

STEVEN W. JOHNSON

JAMES P. STEVENSON

PETER J. O'DWYER

Platinum Chemistry 376

Evolution of Novel Platinum Complexes 377

Mechanism of Action 378

Mechanisms of Resistance 380

Clinical Pharmacology 383

SECTION 5 *Antimetabolites* 388

EDWARD CHU

AUGUSTO C. MOTA

MIKLOS C. FOGARASI

Methotrexate 388**New Antifolates** 393**Other Antifolates** 393**Strategies to Permit Oral Administration of
Fluoropyrimidines** 398**SECTION 6** *Topoisomerase Interactive Agents* 415

CLINTON F. STEWART

MARK J. RATAIN

**Mechanism of Action of Topoisomerase Interactive
Agents** 416**Epipodophyllotoxins** 418**Camptothecin Analogues** 422**Anthracyclines and Related Compounds** 425**Mitoxantrone and Losoxantrone** 427**Dactinomycin (Actinomycin D)** 428**SECTION 7** *Antimicrotubule Agents* 431

ERIC K. ROWINSKY

ANTHONY W. TOLCHER

Microtubules 431**Microtubule-Associated Proteins and Microtubule Motors** 432**Vinca Alkaloids** 432**The Taxanes** 437**Estramustine Phosphate** 445**Novel Compounds Targeting Microtubules** 447**SECTION 8** *Miscellaneous Chemotherapeutic Agents* 452

BRUCE D. CHESON

Homoharringtonine 452**Suramin** 453**Bleomycin** 453**L-Asparaginase** 454**Amifostine** 455**20**
Pharmacology of Cancer Biotherapeutics **461****SECTION 1** *Interferons* 461

JOHN M. KIRKWOOD

**Rationale for Investigation of Interferons: Direct Regulation
of Cell Growth, Differentiation, Antigen Expression; Indirect
Effects Mediated through Modulation of the Host Immune
Response** 461**Clinical Evaluation** 464

SECTION 2 *Interleukin-2* 471

JAMES W. MIER
MICHAEL B. ATKINS

- Isolation, Characterization, and Cloning of Interleukin-2 471
- Interleukin-2 Receptor 472
- Interleukin-2–Activated Signaling Pathways 472
- In Vitro* Effects of Interleukin-2 473
- Preclinical Studies with Interleukin-2 in Tumor-Bearing Mice 473
- Clinical Applications of Interleukin-2 473
- Biology and Pharmacokinetics of Interleukin-2 475
- Attempts to Improve Activity of Interleukin-2–Based Therapy 476

SECTION 3 *Hormonal Therapies* 478

CHARLES ERLICHMAN
CHARLES L. LOPRINZI

- Selective Estrogen Receptor Modulators 478
- Medroxyprogesterone and Megestrol 481
- Aromatase Inhibitors 482
- Gonadotropin-Releasing Hormone Analogues 483
- Antiandrogens 484
- Fluoxymesterone 485
- Diethylstilbestrol and Estradiol (Estrace) 485
- Octreotide 486

SECTION 4 *Differentiation Agents* 489

RAYMOND P. WARRELL, JR.

- Retinoids 489
- Arsenic Trioxide 491
- Histone Deacetylase Inhibitors 491
- Vitamin D 493
- Cytokines and Other Proteins 493

SECTION 5 *Therapeutic Monoclonal Antibodies: General Principles* 495

LOUIS M. WEINER
GREGORY P. ADAMS
MARGARET VON MEHREN

- Immunoglobulin Structure: Structural and Functional Domains 495
- Factors Regulating Antibody-Based Tumor Targeting 495
- Unconjugated Antibodies 497
- Immunoconjugates 500
- Therapeutic Applications 501
- Future Directions 505

SECTION 6 *Antiangiogenesis Agents* 509

JUDAH FOLKMAN

- Guidelines to the Biologic Basis of Antiangiogenic Therapy 509
- Clinical Trials of Angiogenesis Inhibitors 517

21	<i>Clinical Trials in Cancer</i>	521
-----------	---	------------

SECTION 1	<i>Design and Analysis of Clinical Trials</i>	521
	RICHARD SIMON	
	Phase I Clinical Trials	521
	Phase II Clinical Trials	523
	Design of Phase III Clinical Trials	526
	Analysis of Phase III Clinical Trials	531
	Epidemiology of Clinical Trials	537
	Metaanalysis	537
SECTION 2	<i>Research Data Management</i>	539
	DOUGLAS HAGEMAN	
	DIANNE M. REEVES	
	Protocol Development	539
	Protocol Implementation	540
	Information Technology	543
	Data Classification	544
	U.S. Food and Drug Administration Recommendations	544
	Data Validation	544
	Direct Data Capture	545
	Security	545
	Summary	545

PART 3

PRACTICE OF ONCOLOGY

22	<i>Cancer Prevention: Preventing Tobacco-Related Cancers</i>	549
-----------	---	------------

HOWARD K. KOH	
CHRISTINE KANNLER	
ALAN C. GELLER	
Tobacco and Nicotine Addiction	549
Health Effects	550
Smoking Rates and Trends	550
Cigarette Product Modification	552
Spit Tobacco	552
Cigars	552
Environmental Tobacco Smoke	552
Tobacco Industry Advertising Strategies	553
Strategies for Tobacco Control	553
Community Level and State Interventions	555
Tobacco Taxes That Fund Dedicated, Comprehensive Statewide Tobacco Control Programs	556

Mass Media and Counter-Advertising	557
Tobacco Litigation and Tobacco Settlement	557
Proposed U.S. Food and Drug Administration Regulation	558
Conclusion	558

23

Cancer Prevention: Diet and Chemopreventive Agents. **561**

SECTION 1	<i>Fat</i>	561
	WALTER C. WILLETT	
	Fat and Breast Cancer	562
	Fat and Colon Cancer	564
	Fat and Prostate Cancer	565
	Other Cancers	565
	Summary	565
 SECTION 2	 <i>Dietary Fibers</i>	 568
	PETER GREENWALD	
	Sources and Types of Dietary Fiber	568
	Dietary Fiber and Colorectal Cancer	568
	Dietary Fiber and Breast Cancer	572
	Dietary Fiber and Other Cancers	573
	Public Health Implications	573
 SECTION 3	 <i>Retinoids, Carotenoids, and Micronutrients</i>	 575
	SUSAN TAYLOR MAYNE	
	SCOTT M. LIPPMAN	
	Historical Perspective	575
	Retinoid Biology and Pharmacology	576
	Carotenoid Biology and Actions	577
	Clinical Trials	577
	Translational and Intermediate End Point Studies in Retinoid Chemoprevention	586
	New Retinoids and Carotenoids	587
	Conclusions	588
 SECTION 4	 <i>Naturally Occurring Dietary Anticarcinogens</i>	 590
	PETER GREENWALD	
	Carotenoids	590
	Phytoestrogens	591
	Organosulfur and Organoselenium Compounds	591
	Phenolic Compounds	592
	Monoterpenes	593
	Isothiocyanates and Indoles	593
	Protease Inhibitors	594
	Implications for Cancer Prevention	594

SECTION 5 Dietary Carcinogens 595
PETER GREENWALD
Naturally Occurring Dietary Carcinogens 596
Products of Food Preparation and Processing 597
Synthetic Carcinogens in the Diet 599
Future Research Needs 599

**SECTION 6 Aspirin and Other Nonsteroidal Antiinflammatory Drugs
and the Risk of Cancer Development 601**
MICHAEL J. THUN
CHARLES H. HENNEKENS
Pharmacology and Toxicity of Nonsteroidal Antiinflammatory
Drugs 601
Historical Evolution of the Hypothesis That Nonsteroidal
Antiinflammatory Drugs Inhibit Cancer 602
Cellular Mediators of Tumor Inhibition 606
Nonsteroidal Antiinflammatory Drugs and Cancers Other
Than Colorectal Cancer 607
Dose and Duration Issues in Chemoprevention 607

SECTION 7 Physical Activity and Body Weight 610
GRAHAM A. COLDITZ
Colon Cancer 610
Breast Cancer 612
Obesity 613
Relationship between Obesity and Carcinoma 614
Conclusions 614

24
Cancer Prevention: Role of Surgery in Cancer Prevention. 617

RICHARD M. SHERRY
Multiple Endocrine Neoplasia 2 and Familial Medullary
Thyroid Carcinoma 617
Barrett's Esophagus and Esophageal Cancer 618
Breast Cancer 620
Ovarian Cancer 621
Colorectal Cancer 622
Testicular Cancer and Cryptorchidism 624

25
Cancer Screening. 627

BARBARA K. RIMER
JOELLEN SCHILDKRAUT
ROBERT A. HIATT
What Is Cancer Screening? 627
Evaluation of a Screening Test 628
Breast Cancer Screening 629

Cervical Cancer Screening	634
Skin Cancer Screening	634
Prostate Cancer Screening	634
Colorectal Cancer Screening	635
Lung Cancer Screening	637
The Future of Screening	637

26

<i>Cancer Diagnosis: Molecular Pathology</i>	641
--	------------

JOSÉ COSTA

CARLOS CORDON-CARDO

Role of Molecular Pathology in Clinical Oncology and Translational Research	641
Use of Human Tissue Samples for Molecular Analyses	642
Overview of the Technological Approaches to Molecular Diagnostics	643
Applications of Molecular Markers: Diagnostic Molecular Pathology	651
Considerations for the Future	655

27

<i>Cancer Diagnosis: Imaging</i>	659
--	------------

SECTION 1 *Computed Tomography* 659

ELLIOT K. FISHMAN

BRUCE A. URBAN

Liver	659
Pancreas	660
Kidney	661
Adrenal Gland	662
Small Bowel and Colon	663
Esophagus and Stomach	665
Lungs and Mediastinum	665
Musculoskeletal System	668
Central Nervous System	668
Summary	668

SECTION 2 *Magnetic Resonance Imaging* 669

ARTHUR E. LI

DAVID A. BLUEMKE

Basic Principles	669
Brain	671
Spine	672
Head and Neck	672
Breast	673
Liver	673
Adrenal Glands	674
Kidney	675
Uterus	675
Cervix	675
Ovary	676

Prostate	676
Bladder	677
Musculoskeletal System	677

SECTION 3	<i>Functional and Metabolic Imaging</i>	679
	MARTIN G. POMPER	
	Techniques for Functional and Metabolic Imaging	679
	New Functional and Metabolic Imaging Modalities	687
	Summary	687

SECTION 4	<i>Interventional Radiology</i>	690
	JEAN-FRANCOIS H. GESCHWIND	
	Diagnostic Procedures	690
	Therapeutic Interventions	692

SECTION 5	<i>Ultrasound</i>	708
	ULRIKE M. HAMPER	
	Ultrasonography Applications	708
	Urologic Oncology	708
	Gynecologic Oncology	709
	Medical Oncology	710
	Ultrasonographically Guided Interventional Procedures	712
	Summary	713

SECTION 6	<i>Radionuclide Imaging</i>	714
	E. EDMUND KIM	
	Indirect Radionuclide Tumor Imaging	714
	Direct Radionuclide Tumor Imaging	716

28	<i>Cancer Diagnosis: Endoscopy</i>	721
-----------	---	------------

ROBERT C. KURTZ
ROBERT J. GINSBERG

Upper Gastrointestinal Endoscopy	721
Endoscopic Ultrasonography	722
Sigmoidoscopy	724
Colonoscopy	725
Laparoscopy	726
Endoscopic Retrograde Cholangiopancreatography	727
Small Intestinal Endoscopy: Enteroscopy	729
Percutaneous Endoscopic Gastrostomy	729
Bronchoscopy	729
Mediastinoscopy	733
Thoracoscopy	734

29

Specialized Techniques in Cancer Management. 739**SECTION 1 Laparoscopy 739**

ALAN T. LEFOR

Laparoscopic Physiology 740

Port-Site Metastases 741

Laparoscopy in the Diagnosis of Malignancy 742

Laparoscopy in the Staging of Malignancy 743

Laparoscopy in the Treatment of Malignancy 750

Laparoscopy in the Palliation of Malignancy 756

The Future of Laparoscopy in the Care of the Patient
with Cancer 757**SECTION 2 Vascular Access and Specialized Techniques
of Drug Delivery 760**

STEVEN K. LIBUTTI

MCDONALD K. HORNE III

Catheter Types 760

Insertion Technique 762

Selecting the Appropriate Catheter 764

Catheter-Related Complications 765

SECTION 3 Isolation Perfusion 769

H. RICHARD ALEXANDER

Principles of Isolation Perfusion 769

Results of Isolation Perfusion 771

Conclusions 775

SECTION 4 Intensity-Modulated Radiation Therapy 777

C. CLIFTON LING

CHEN CHUI

THOMAS LOSASSO

CHANDRA BURMAN

MARGIE HUNT

GIGAS MAGERAS

HOWARD IRA AMOLS

MICHAEL J. ZELEFSKY

ZVI Y. FUKS

STEVEN A. LEIBEL

Process of Intensity-Modulated Radiotherapy 777

Clinical Experience 783

Consideration of Treatment Uncertainties 785

Development and Research Issues 785

30

Cancer of the Head and Neck 789**SECTION 1 *Molecular Biology of Head and Neck Tumors* 789**

DAVID SIDRANSKY

Genetic Susceptibility 789

Cytogenetic Alterations 790

Protooncogenes 790

Suppressive Growth Regulation 790

Tumor Suppressor Genes 791

Field Cancerization 792

Molecular Epidemiology 793

Human Papillomavirus 793

Diagnostics 793

SECTION 2 *Tumors of the Nasal Cavity and Paranasal Sinuses, Nasopharynx, Oral Cavity, and Oropharynx* 797

STIMSON P. SCHANTZ

LOUIS B. HARRISON

ARLENE A. FORASTIERE

Anatomy 797

Pathology 797

Staging and Screening 797

Treatment 800

Principles of Chemotherapy: Recurrent and Metastatic Disease 804

Biologic Targeted Therapies 811

Principles of Chemotherapy: Previously Untreated Disease 811

Postoperative Adjuvant Treatment 813

Principles of Chemoprevention 817

Posttreatment Rehabilitation 819

Nasal Cavity and Paranasal Sinuses 819

Nasopharynx 824

Oral Cavity 832

Lip 833

Alveolar Ridge and Retromolar Trigone 834

Floor of Mouth 836

Tongue 839

Hard Palate 841

Buccal Mucosa 841

Rehabilitation of the Oral Cancer Patient 842

Oropharynx 842

Base of Tongue 843

Tonsil, Tonsillar Pillar, and Soft Palate 846

Pharyngeal Wall 850

SECTION 3 *Tumors of the Larynx and Hypopharynx* 861

ROY B. SESSIONS

LOUIS B. HARRISON

ARLENE A. FORASTIERE

Larynx 861

Hypopharynx 878

SECTION 4	<i>Tumors of the Salivary Glands and Paragangliomas</i>	886
	ROY B. SESSIONS	
	LOUIS B. HARRISON	
	ARLENE A. FORASTIERE	
	Major Salivary Gland Tumors	886
	Minor Salivary Gland Tumors	897
	Paragangliomas	900
SECTION 5	<i>Rehabilitation after Treatment for Head and Neck Cancer</i>	907
	SUSAN D. MILLER	
	ROY B. SESSIONS	
	Pretreatment Assessment	907
	Diagnostic Evaluation	907
	Posttreatment Intervention	908
	Volunteer and Support Organizations	914

31

Cancer of the Lung **917**

SECTION 1	<i>Molecular Biology of Lung Cancer</i>	917
	YOSHITAKA SEKIDO	
	KWUN M. FONG	
	JOHN D. MINNA	
	Genetic and Epigenetic Alterations in Lung Cancers	917
	Protooncogenes and Growth Stimulation	918
	Tumor Suppressor Genes and Growth Suppression	920
	Other Biologic Abnormalities for Lung Cancer Development	922
	Molecular Tools in the Lung Cancer Clinic	924
SECTION 2	<i>Non-Small Cell Lung Cancer</i>	925
	ROBERT J. GINSBERG	
	EVERETT E. VOKES	
	KENNETH ROSENZWEIG	
	Epidemiology	925
	Pathology	927
	Diagnosis and Staging	933
	Pretreatment Prognostic Factors	939
	Occult Disease	942
	Chemoprevention	943
	Overview of Invasive Lung Cancer Management: Treatment Modalities	943
	Specifics of Lung Cancer Management	951
SECTION 3	<i>Small Cell Lung Cancer</i>	983
	JOHN MURREN	
	ELI GLATSTEIN	
	HARVEY I. PASS	
	Epidemiology and Etiology	983
	Pathology	984

- Clinical Presentation 985
- Staging Evaluation and Prognostic Factors 986
- Treatment 988
- Combination Chemotherapy 990
- Duration of Chemotherapy 992
- General Approach to Patients with Limited Disease 992
- General Approach to Patients with Extensive Disease 1000
- Strategies to Optimize Chemotherapy Response 1001
- Management of Small Cell Lung Cancer in the Elderly and Infirm 1006
- Biologic Response Modifiers and Other Treatments 1007
- Treatment at Relapse 1008
- Treatment Outcome and Long-Term Survival 1009
- Extrapulmonary Small Cell Carcinoma 1010

32
Neoplasms of the Mediastinum. 1019

ROBERT B. CAMERON
PATRICK J. LOEHRER
CHARLES R. THOMAS, JR.

- Anatomy 1019
- Incidence and Pathology 1019
- Diagnostic Considerations 1020
- Thymic Neoplasms 1023
- Germ Cell Tumors 1028
- Mesenchymal Tumors 1030
- Neurogenic Tumors 1031
- Primary Cardiac Malignancies 1033

33
Cancers of the Gastrointestinal Tract. 1037

SECTION 1 *Molecular Biology of Gastrointestinal Cancers 1037*

ERIC R. FEARON

- Colorectal Cancer as a Model System 1038
- The Adenoma-Carcinoma Sequence in the Colon 1038
- Inherited Colorectal Cancer Syndromes 1038
- Oncogene and Tumor Suppressor Gene Mutations in Colorectal Tumor Progression 1043
- Gene Defects in Pancreatic Carcinoma 1045
- Gene Defects in Esophageal Adenocarcinoma 1046
- Potential Clinical Applications of Molecular Advances 1047

SECTION 2 *Cancer of the Esophagus 1051*

DAVID S. SCHRUMP
NASSER K. ALTORKI
ARLENE A. FORASTIERE
BRUCE D. MINSKY

- Epidemiology 1051
- Anatomy 1052

Histology	1053
Predisposing Conditions	1054
Molecular Biology	1057
Clinical Presentation	1058
Treatment	1060

SECTION 3	<i>Cancer of the Stomach</i>	1092
	MARTIN S. KARPEH	
	DAVID P. KELSEN	
	JOEL E. TEPPER	
	Epidemiology	1092
	Etiology and Pathogenesis	1093
	Pathology and Tumor Biology	1095
	Clinical Presentation	1097
	Pretreatment Staging	1098
	Pathologic Staging and Prognosis	1099
	Treatment of Localized Disease	1101
	Adjuvant Therapy	1106
	Palliative Treatment of Gastric Cancer	1116
	Predicting Response	1120
	Chemotherapy versus Best Supportive Care	1121
	Surgery for Palliation	1121

SECTION 4	<i>Cancer of the Pancreas</i>	1126
	DOUGLAS B. EVANS	
	JAMES L. ABBRUZZESE	
	CHRISTOPHER G. WILLETT	
	Epidemiology	1126
	Etiologic Factors	1126
	Pathology and Molecular Pathogenesis	1127
	Clinical Signs and Symptoms	1129
	Natural History and Patterns of Treatment Failure	1129
	Clinical and Pathologic (Surgical) Staging	1131
	Pretreatment Diagnostic Studies	1132
	Treatment of Potentially Resectable Disease	1136
	Palliative Methods of Biliary and Gastric Decompression	1143
	Treatment of Locally Advanced Disease	1145
	Treatment of Metastatic and Recurrent Disease	1148

SECTION 5	<i>Cancer of the Liver and Biliary Tree</i>	1162
	YUMAN FONG	
	NANCY KEMENY	
	THEODORE S. LAWRENCE	
	Hepatocellular Carcinoma	1162
	Other Primary Tumors of the Liver	1177
	Cholangiocarcinoma	1178
	Tumors of the Gallbladder	1187

SECTION 6	<i>Cancer of the Small Intestine</i>	1204
	DANIEL G. COIT	
	History	1204
	Incidence	1204

Etiology	1204
Anatomy	1205
Pathology	1205
Presentation	1205
Diagnosis	1206
Management	1207

SECTION 7 *Cancer of the Colon* 1216

JOHN M. SKIBBER
BRUCE D. MINSKY
PAULO M. HOFF

Anatomy	1216
Epidemiology	1217
Etiology	1218
Primary Prevention	1219
Secondary Prevention	1220
Clinical Risk Factor: Age	1220
Genetic Risk Factors	1221
Predisposing Medical Conditions	1223
Screening	1224
Diagnosis	1227
Spread of Colorectal Cancer	1229
Staging and Prognostic Features	1230
Treatment of Precancerous Conditions	1238
Management of Potentially Curable Colon Cancer	1240
Treatment of Initially Advanced Colon Cancer	1254
Follow-Up after Potentially Curative Treatment	1255
Chemotherapy for Metastatic Colorectal Cancer	1256
Miscellaneous Colorectal Tumors	1262

SECTION 8 *Cancer of the Rectum* 1271

JOHN M. SKIBBER
PAULO M. HOFF
BRUCE D. MINSKY

Anatomy	1271
Diagnosis	1271
Clinical Staging System	1274
Treatment of Resectable Rectal Cancer	1275
Treatment of Invasive Cancer by Nonradical Approaches	1279
Results of Treatment of Rectal Cancer	1281
Radiation Therapy Alone for Resectable Rectal Cancer	1284
Adjuvant Therapy and Sphincter-Saving Operations as an Alternative to Abdominoperineal Resection	1285
Local Excision and Postoperative Radiation Therapy	1285
Preoperative Radiation Therapy Followed by Surgery	1288
Low Anterior Resection and Coloanal Anastomosis	1289
Adjuvant Radiation Therapy for Resectable Rectal Cancer	1291
Preoperative and Postoperative Radiation Therapy	1295
Selected Controversies in the Role of Preoperative Therapy	1295
Radical Surgery and Adjuvant Postoperative Combined Modality Therapy for Resectable Rectal Cancer	1296

Future of Adjuvant Therapy	1298
Complications of Pelvic Radiation Therapy	1299
Minimizing Toxicity of Radiation Therapy	1301
Treatment of Locally Advanced and Unresectable Rectal Cancer	1305
Intraoperative or Postoperative Radiation Therapy for Residual Disease	1309
Investigational Radiation Therapy Approaches	1311
Treatment of Patients with Synchronous Metastatic Disease	1312
Follow-Up after Potentially Curative Treatment	1312
Treatment of Recurrence	1312

SECTION 9 *Cancer of the Anal Region* 1319

BRUCE D. MINSKY	
JOHN P. HOFFMAN	
DAVID P. KELSEN	
Epidemiology and Etiology	1319
Anal Cancer and Acquired Immunodeficiency Syndrome	1320
Molecular and Chromosomal Abnormalities	1320
Other Associations	1320
Animal Studies	1321
Anatomy	1321
Pathology	1322
Precancerous Changes	1322
Squamous Cell Cancer	1323
Radiation Therapy Treatment Techniques	1334
Inguinal Node Involvement	1336
Residual or Recurrent Cancer	1336
Metastatic Disease	1337
Follow-Up	1338
Anorectal Melanoma	1338
Adenocarcinoma	1339
Sarcoma	1339
Treatment of the Human Immunodeficiency Virus-Positive Patient	1339
Future Directions	1339

34

Cancers of the Genitourinary System 1343

SECTION 1 *Molecular Biology of Genitourinary Cancers* 1343

W. MARSTON LINEHAN	
BERTON ZBAR	
FREDRICK LEACH	
CARLOS CORDON-CARDO	
WILLIAM ISAACS	
Kidney Cancer	1343
Prostate Cancer	1348
Bladder Cancer	1352

SECTION 2 *Cancer of the Kidney and Ureter* 1362

W. MARSTON LINEHAN
BERTON ZBAR
SUSAN E. BATES
MICHAEL J. ZELEFSKY
JAMES C. YANG

Renal Carcinoma 1362

Carcinoma of the Renal Pelvis and Ureter 1384

SECTION 3 *Cancer of the Bladder* 1396

HARRY W. HERR
WILLIAM U. SHIPLEY
DEAN F. BAJORIN

Epidemiology 1396

Clinical Presentation and Diagnosis 1397

Pathogenesis 1399

Treatment 1400

Summary 1414

SECTION 4 *Cancer of the Prostate* 1418

PETER R. CARROLL
KEITH L. LEE
ZVI Y. FUKS
PHILIP W. KANTOFF

Normal Prostate Anatomy and Histology 1418

**Pathology and Patterns of Progression of Prostate
Cancer** 1420

**Premalignant Lesions (Prostatic Intraepithelial
Neoplasia)** 1422

Staging 1423

Epidemiology 1424

Chemoprevention and Diet 1425

Prostate Cancer Early Detection 1427

Initial Cancer Staging and Risk Assessment 1431

**Treatment Selection for Nonmetastatic (T1–T3N0M0)
Disease** 1435

**Treatment Selection for Advanced Disease: Metastatic
and Local Regional Disease** 1459

Future Therapies: Novel Targets 1467

SECTION 5 *Cancer of the Urethra and Penis* 1480

HARRY W. HERR
GUIDO DALBAGNI
DEAN F. BAJORIN
WILLIAM U. SHIPLEY

Carcinoma of the Male Urethra 1480

Carcinoma of the Female Urethra 1483

Cancer of the Penis 1484

35

Cancer of the Testis 1491

GEORGE J. BOSL
DEAN F. BAJORIN
JOEL SHEINFELD
ROBERT J. MOTZER
R. S. K. CHAGANTI

Background: Incidence 1491

Epidemiology 1491

Initial Presentation and Management 1492

Histology 1492

Staging 1496

Management of Clinical Stage I Disease 1500

Management of Clinical Stage II (Low Tumor Burden) 1504

Management of Stage II and Stage III Disease (High Tumor Burden) 1505

Management of Relapse after Chemotherapy 1510

Treatment Sequelae 1511

Midline Tumors of Uncertain Histogenesis 1512

Other Testicular Tumors 1513

36

Gynecologic Cancers 1519

SECTION 1 *Molecular Biology of Gynecologic Cancers* 1519

SETSUKE KUKI CHAMBERS

Endometrial Cancer 1519

Ovarian Cancer 1520

Cervical and Vulvar Cancer 1522

SECTION 2 *Cancer of the Cervix, Vagina, and Vulva* 1526

PATRICIA J. EIFEL
JONATHAN S. BEREK
JAMES T. THIGPEN

Carcinoma of the Cervix 1526

Carcinoma of the Cervical Stump 1549

Carcinoma of the Vagina 1550

Carcinoma of the Vulva 1556

SECTION 3 *Cancers of the Uterine Body* 1573

THOMAS W. BURKE
PATRICIA J. EIFEL
FRANCO M. MUGGIA

Endometrial Carcinoma 1573

Uterine Sarcomas 1586

SECTION 4 *Gestational Trophoblastic Diseases* 1594

FRANCO M. MUGGIA
PATRICIA J. EIFEL
THOMAS W. BURKE

Epidemiology 1594

Pathology and Biology 1594

Clinical Diagnosis and Human Chorionic Gonadotropin	1594
Choriocarcinoma	1595

SECTION 5 *Ovarian Cancer, Fallopian Tube Carcinoma, and Peritoneal Carcinoma* 1597

ROBERT F. OZOLS
PETER E. SCHWARTZ
PATRICIA J. EIFEL

Ovarian Cancer	1597
Borderline Tumors	1624
Sex Cord–Stromal Tumors	1624
Extraovarian Peritoneal Carcinoma	1625
Germ Cell Tumors of the Ovary	1626
Nondysgerminomatous Germ Cell Tumors	1627
Fallopian Tube Cancer	1628

37

Cancer of the Breast **1633**

SECTION 1 *Molecular Biology of Breast Cancer* 1633

ROBERT B. DICKSON
MARC E. LIPPMAN

Genetics	1633
Steroid and Growth Factor Pathways of Cellular Regulation	1635
The Cell Cycle and Cell Death	1641
Process of Malignant Progression	1643
Implications of Molecular Biology for Tumor Prevention, Early Detection, Prognosis, and Response to Therapy	1645

SECTION 2 *Malignant Tumors of the Breast* 1651

ERIC P. WINER
MONICA MORROW
C. KENT OSBORNE
JAY R. HARRIS

Risk Factors for Breast Cancer	1652
Management of the High-Risk Patient	1655
Breast Cancer Prevention	1656
Biopsy Techniques for Suspicious Breast Lesions	1657
Ductal Carcinoma <i>In Situ</i>	1659
Lobular Carcinoma <i>In Situ</i>	1663
Staging of Breast Cancer	1664
Local Management of Invasive Breast Cancer	1667
Local Recurrence	1680
Breast Reconstruction	1682
Special Therapeutic Problems	1683
Prognostic and Predictive Factors	1687
Adjuvant Drug (Systemic) Therapy	1688
Adjuvant Chemotherapy	1692
Therapy of Locally Advanced and Inflammatory Breast Cancer	1697
Follow-Up after Primary Treatment	1698
Management of Patients with Metastatic Breast Cancer	1699

SECTION 3 *Rehabilitation after Treatment for Cancer of the Breast* 1717JOSEPH J. DISA
JEANNE A. PETREK

Delayed versus Immediate Reconstruction 1717

Prosthetic Reconstruction 1718

Autologous Tissue Reconstruction 1719

Postmastectomy after Breast Irradiation 1721

Skin-Sparing Mastectomy with Immediate Reconstruction 1721

Lymphedema 1722

38*Cancer of the Endocrine System* **1727****SECTION 1** *Molecular Biology of Endocrine Tumors* 1727TERRY C. LAIRMORE
SAMUEL A. WELLS, JR.
JEFFREY F. MOLEY

Multiple Endocrine Neoplasia Syndromes 1727

Molecular Pathogenesis of Sporadic Thyroid Neoplasms 1733

Genetic Abnormalities in Parathyroid Neoplasms 1735

Other Genetic Loci Implicated in Familial Hypercalcemic
Syndromes 1736

Parathyroid Carcinoma 1737

Genetic Abnormalities in Adrenal Neoplasms 1737

Summary 1737

SECTION 2 *Thyroid Tumors* 1740DOUGLAS L. FRAKER
MONICA SKARULIS
VIRGINIA LIVOLSI

Thyroid Nodules 1741

Well-Differentiated Thyroid Carcinoma 1742

Anaplastic Thyroid Cancer 1755

Medullary Thyroid Cancer 1756

Thyroid Lymphoma 1759

Secondary Thyroid Malignancy 1759

SECTION 3 *Parathyroid Tumors* 1763

DOUGLAS L. FRAKER

Primary Hyperparathyroidism 1763

SECTION 4 *Adrenal Tumors* 1770JEFFREY A. NORTON
HOP N. LE

Pathology of the Adrenal Cortex 1770

Adrenal Cortical Adenoma 1770

Adrenal Cortical Carcinoma 1770

Clinical Presentations of Adrenal Cortical Neoplasms 1771

Treatment of Adrenal Cortical Neoplasms 1777

Ectopic Adrenocorticotrophic Hormone Syndrome	1780
Pheochromocytoma	1780

SECTION 5 *Pancreatic Endocrine Tumors* 1788

H. RICHARD ALEXANDER
ROBERT T. JENSEN

Introduction	1788
Pathogenesis, Pathologic Features, and Tumor Biology	1788
Clinical Presentation and Diagnosis	1792
Imaging and Localization of Pancreatic Endocrine Tumors	1796
Treatment of Resectable Disease	1798
Treatment of Metastatic Disease	1806

SECTION 6 *Carcinoid Tumors and the Carcinoid Syndrome* 1813

ROBERT T. JENSEN
GERARD M. DOHERTY

Pathology and Tumor Histology	1813
Molecular Pathogenesis	1816
Clinical Features	1816
Carcinoid Syndrome	1817
Treatment of the Carcinoid Tumor	1826

SECTION 7 *Multiple Endocrine Neoplasias* 1834

GERARD M. DOHERTY
ROBERT T. JENSEN

Multiple Endocrine Neoplasia Type 1	1834
Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Types 2A and 2B	1836

39

Sarcomas of the Soft Tissue and Bone 1841

SECTION 1 *Soft Tissue Sarcoma* 1841

MURRAY F. BRENNAN
KALED M. ALEKTIAR
ROBERT G. MAKI

Incidence	1841
Etiology and Genetics	1841
Distribution	1843
Pathologic Classification	1844
Grading of Sarcoma	1847
Differential Diagnosis	1848
Clinicopathologic Features of Specific Types of Benign and Malignant Soft Tissue Tumors	1848
Clinical Presentation	1855
Differential Diagnosis	1856
Management of Extremity and Superficial Truncal Soft Tissue Sarcoma	1860
Radiation Therapy	1861
Special Considerations	1864

Definitive Radiation	1865
Adjuvant Chemotherapy	1865
Preoperative Chemotherapy	1870
Intraarterial Chemotherapy	1870
Hyperthermia and Limb Perfusion	1871
Special Features of the Management of Sarcomas of Nonextremity Sites	1871
Management of Head and Neck Sarcoma	1873
Management of Breast Sarcoma	1873
Serious Complications of Primary Treatment	1874
Prognostic Factors for Outcome	1874
Quality of Life and Functional Outcome	1875
Treatment of Local Recurrence	1875
Management of Advanced Disease	1876
Systemic Therapy for Advanced Disease	1876
Response by Histologic Subtype and Site	1880
Recommendations for Patients with Advanced Disease	1883
Future Directions	1883

SECTION 2 *Sarcomas of Bone* 1891

MARTIN M. MALAWER	
MICHAEL P. LINK	
SARAH S. DONALDSON	
Classification and Types of Bone Tumors	1891
Radiographic Evaluation and Diagnosis	1892
Natural History	1893
Staging Bone Tumors	1894
Preoperative Evaluation	1895
Biopsy Technique and Timing	1896
Restaging after Preoperative Chemotherapy	1896
Surgical Management of Skeletal Tumors	1898
Principles and Techniques of Limb-Sparing Surgery	1898
Amputations	1900
Cryosurgery	1901
Chemotherapy for Bone Sarcomas	1901
Radiotherapy for Bone Tumors	1907
Benign Bone Tumors	1908
Malignant Bone Tumors	1910

40

Benign and Malignant Mesothelioma 1937

SECTION 1 *Molecular Biology of Mesothelioma* 1937

JOSEPH R. TESTA	
HARVEY I. PASS	
MICHELE CARBONE	
Mechanism of Asbestos-Induced Oncogenesis	1937
Cytogenetic Assessment of Malignant Mesotheliomas	1938
Deletion Mapping	1938
Alterations of Tumor Suppressor Genes in Mesothelioma	1939
Simian Virus 40	1939

Conclusions 1941

Summary 1942

SECTION 2 *Management of Mesothelioma* 1943

KAREN H. ANTMAN

HARVEY I. PASS

PETER B. SCHIFF

Epidemiology 1943

Biology of Mesothelioma: Ploidy Studies 1945

Diagnosis of Mesothelioma 1945

Malignant Pleural Mesothelioma 1947

Multimodality Treatment 1959

Malignant Peritoneal Mesothelioma 1961

Malignant Mesothelioma of the Tunica Vaginalis Testis 1963

Malignant Mesothelioma of the Pericardium 1964

Benign Mesothelioma 1964

41

Cancer of the Skin 1971

SECTION 1 *Molecular Biology of Skin Cancer* 1971

DOUGLAS E. BRASH

ALLEN E. BALE

Skin Carcinogens 1971

Genetic Events 1972

Cellular Events 1973

Therapeutics 1974

SECTION 2 *Management of Skin Cancer* 1976

DAVID J. LEFFELL

JOHN A. CARUCCI

Diagnosis 1976

General Approach to Management of Skin Cancer 1976

**Nonmelanoma Skin Cancer and Precancerous
Lesions** 1979

Carcinoma Metastatic to Skin 1998

Conclusion 1998

42

Melanoma 2003

SECTION 1 *Molecular Biology of Cutaneous Melanoma* 2003

MEENHARD HERLYN

KAPAETTU SATYAMOORTHY

Etiology of Melanoma 2003

Genetics of Melanoma 2004

**Functional Significance of Specific Gene Mutations
in Melanoma** 2005

Biology of Melanoma Development and Progression	2007
Biologic Basis of Melanoma Progression	2008

SECTION 2 *Cutaneous Melanoma* 2012

MICHAEL T. LOTZE	
RAMSEY M. DALLAL	
JOHN M. KIRKWOOD	
JOHN C. FLICKINGER	
Epidemiology	2012
Risk Factors, Prevention, and Screening	2015
Staging of Melanoma	2022
Imaging of Malignant Melanoma	2028
Radiobiology of Melanoma	2028
Stage I and II Disease: Management of Primary Melanoma	2029
Stage I and II Disease: Examination of the Lymph Node Basin	2032
Stage III Disease: Management of the Clinically Positive Nodal Basin	2037
Stage III Disease: Management of In-Transit Disease	2039
Adjuvant Medical Therapy	2044
Treatment of Stage IV Disease	2048
Cytotoxic Chemotherapy	2051
Immunotherapy of Metastatic Disease	2053
Management of Melanoma in the Pregnant Patient	2056
Future Prospects for the Biologic Therapy of Patients with Melanoma	2056

SECTION 3 *Intraocular Melanoma* 2070

JOSÉ A. SAHEL	
ARTHUR S. POLANS	
MINESH P. MEHTA	
RICHARD M. AUCHTER	
DANIEL M. ALBERT	
Epidemiology	2070
Etiology and Histogenesis of Ocular Melanomas	2071
Histopathology, Prognostic Parameters, and Natural History	2072
Diagnosis of Uveal Melanomas: Choroidal and Ciliary Body Melanomas	2075
Management	2078
Future Directions for Research	2085

43

Neoplasms of the Central Nervous System 2091

SECTION 1 *Molecular Biology of Central Nervous System Neoplasms* 2091

DAVID N. LOUIS	
WEBSTER K. CAVENEE	
Diffuse, Fibrillary Astrocytomas	2091
Other Gliomas	2093
Medulloblastomas	2096

Meningiomas	2096
Peripheral Nerve Tumors	2097
Miscellaneous Tumors	2097
Neurologic Tumor Syndromes	2098
Summary	2098

SECTION 2 *Neoplasms of the Central Nervous System* 2100

VICTOR A. LEVIN
STEVEN A. LEIBEL
PHILIP H. GUTIN

Incidence and Classification	2100
Genetic, Molecular, Environmental, Viral, and Other Factors Associated with Central Nervous System Neoplasia	2101
Anatomic and Clinical Considerations	2102
Neurodiagnostic Tests	2108
Surgery	2112
Radiation Therapy	2114
Chemotherapy	2119
Cerebral Astrocytomas	2120
Brain Stem Gliomas	2127
Cerebellar Astrocytomas	2129
Optic, Chiasmal, and Hypothalamic Gliomas	2130
Oligodendrogliomas	2131
Ependymoma	2133
Meningiomas	2135
Primitive Neuroepithelial Tumors	2138
Medulloblastoma	2139
Pineal Region Tumors	2142
Pituitary Adenomas	2145
Craniopharyngiomas	2146
Cerebellopontine Vestibular Schwannomas	2147
Glomus Jugulare Tumors	2148
Chordomas	2149
Hemangioblastomas and Hemangiomas	2150
Choroid Plexus Papilloma and Carcinoma	2151
Spinal Axis Tumors	2152

44

Cancers of Childhood 2161

SECTION 1 *Molecular Biology of Childhood Cancers* 2161

LEE J. HELMAN
DAVID MALKIN

Tumor Suppressor Genes	2162
Retinoblastoma: The Paradigm	2162
Wilms' Tumor: Three Distinct Loci	2163
Neurofibromatoses	2164
Neuroblastoma	2164
Ewing's Sarcoma Family of Tumors	2165
Rhabdomyosarcoma	2165

Hereditary Syndromes Associated with Tumors of Childhood	2166
Predictive Testing for Germline Mutations and Childhood Cancers	2167

SECTION 2 *Solid Tumors of Childhood* 2169

DAVID H. EBB	
DANIEL M. GREEN	
ROBERT C. SHAMBERGER	
NANCY J. TARBELL	
Epidemiology	2169
Management of Childhood Cancer	2170
Wilms' Tumor	2171
Favorable Histology Wilms' Tumor	2176
Neuroblastoma	2177
Retinoblastoma	2182
Treatment	2183
Advanced Unilateral Disease	2184
Limited Unilateral or Limited Bilateral Disease	2184
Bilateral Disease	2184
Chemotherapy	2185
Rhabdomyosarcoma	2185
Ewing's Sarcoma and Peripheral Primitive Neuroectodermal Tumor	2193
Primary Hepatic Tumors	2197
Germ Cell Tumors	2200
Clinical Presentation and Treatment by Anatomic Site	2202

45

<i>Lymphomas</i>	2215
----------------------------	------

SECTION 1 *Molecular Biology of Lymphomas* 2215

RICCARDO DALLA-FAVERA	
GIANLUCA GAIDANO	
Histogenetic Pathways of Lymphoma	2215
General Mechanisms of Genetic Lesions in Lymphoma	2217
Molecular Pathogenesis of B-Cell Non-Hodgkin's Lymphoma	2220
Molecular Pathogenesis of T-Cell Non-Hodgkin's Lymphoma	2228
Molecular Pathogenesis of Hodgkin's Lymphoma	2230
Genetic Lesions as Clinical Tools in the Management of Lymphoma	2230

SECTION 2 *Leukemias and Lymphomas of Childhood* 2235

HOWARD J. WEINSTEIN	
NANCY J. TARBELL	
Leukemias	2235
Non-Hodgkin's Lymphoma	2245
Hodgkin's Disease	2250

SECTION 3	<i>Non-Hodgkin's Lymphomas</i>	2256
	JAMES O. ARMITAGE PETER M. MAUCH NANCY LEE HARRIS PHILIP BIERMAN	
	Epidemiology	2256
	Etiology	2258
	Principles of Management of Non-Hodgkin's Lymphoma	2273
	Specific Disease Entities	2276
	Special Clinical Situations	2298
SECTION 4	<i>Cutaneous T-Cell Lymphomas</i>	2316
	LYNN D. WILSON GLENN W. JONES BARRY M. KACINSKI RICHARD L. EDELSON PETER W. HEALD	
	Pathobiology	2316
	Epidemiology	2317
	Etiology	2317
	Clinical Presentation	2317
	Approach to Patients with Mycosis Fungoides	2318
	Patient Evaluation	2320
	Principles of Therapy	2321
SECTION 5	<i>Primary Central Nervous System Lymphoma</i>	2330
	LISA M. DEANGELIS JOACHIM YAHALOM	
	Clinical Features	2330
	Diagnostic Tests	2331
	Pathology	2332
	Management	2332
SECTION 6	<i>Hodgkin's Disease</i>	2339
	VOLKER DIEHL PETER M. MAUCH NANCY LEE HARRIS	
	History	2339
	Etiology and Epidemiology	2339
	Biology and Cell of Origin	2341
	Pathology	2344
	Diagnosis and Staging	2350
	Clinical Presentation	2352
	Treatment Methods	2353
	Choice of Treatment	2355
	Clinical Features	2374
	Treatment Results	2375
	Transformation to Non-Hodgkin's Lymphoma	2375
	Consequences for Future Treatment	2375
	Hodgkin's Disease in the Elderly Patient	2375
	Hodgkin's Disease During Pregnancy	2376

Hodgkin's Disease in Human Immunodeficiency	
Virus-Positive Patients	2376
Sequelae	2377
Quality of Life	2379
New Drugs in Hodgkin's Disease	2379
Immunotherapy	2380

46

<i>Leukemias</i>	2389
------------------------	-------------

SECTION 1 *Molecular Biology of Leukemias* 2389

CLARA D. BLOOMFIELD	
MICHAEL A. CALIGIURI	
Gene Fusions in Leukemia	2392
Gene Activation in Leukemia	2399
Tumor Suppressor Genes in Leukemia	2400
Molecular Monitoring of Leukemia	2401

SECTION 2 *Acute Leukemias* 2404

DAVID A. SCHEINBERG	
PETER MASLAK	
MARK WEISS	
Epidemiology and Etiology	2405
Biology of Acute Leukemias	2407
Diagnosis and Classification of Acute Leukemias	2408
Treatment of Relapsed Acute Myelogenous Leukemias	2420
Acute Promyelocytic Leukemia	2422
Conclusions	2428

SECTION 3 *Chronic Leukemias* 2433

Section 3.1 *Chronic Myelogenous Leukemia* 2433

HAGOP M. KANTARJIAN	
STEFAN FADERL	
MOSHE TALPAZ	
Epidemiology	2433
Etiology and Pathogenesis	2434
Diagnosis and Clinical Course	2435
Treatment	2436
Conclusions	2445

Section 3.2 *The Chronic Lymphocytic Leukemias* 2447

BRUCE D. CHESON	
Cell of Origin	2447
Immune Function and Autoimmunity in Chronic Lymphocytic Leukemia	2448
Cytogenetics	2448
Molecular Biology and Genetics	2448
Diagnosis	2448
Clinical Features	2451

Staging and Prognostic Factors	2452
Therapy	2453
Related B-Cell Leukemias	2458

SECTION 4	<i>Plasma Cell Neoplasms</i>	2465
	NIKHIL C. MUNSHI	
	GUIDO TRICOT	
	BART BARLOGIE	
	History	2466
	Epidemiology	2466
	Etiology	2467
	Pathogenesis	2467
	Clinical Manifestations	2471
	Diagnosis	2473
	Differential Diagnosis	2479
	Prognostic Variables	2480
	Treatment	2482
	Waldenström's Macroglobulinemia	2491
	Perspective	2493

SECTION 5	<i>Myelodysplastic Syndromes</i>	2499
	HAGOP M. KANTARJIAN	
	ELIHU ESTEY	
	Incidence	2499
	Etiology	2499
	Classification and Risk Groups	2500
	Biology and Pathophysiology	2501
	Clinical Manifestations	2502
	Laboratory Features	2502
	Differential Diagnosis	2503
	Significance of the 30% Blast Cutoff to Distinguish High-Risk Myelodysplastic Syndromes from Acute Myeloid Leukemia	2503
	Specific Subtypes of Myelodysplastic Syndromes	2503
	Therapy	2504
	Summary	2507

47

<i>Paraneoplastic Syndromes</i>	2511
SUSANNE M. ARNOLD	
ROY PATCHELL	
ANDREW M. LOWY	
KENNETH A. FOON	
Endocrinologic Manifestations of Cancer	2511
Hematologic Manifestations of Cancer	2516
Gastrointestinal Manifestations of Cancer	2518
Renal Manifestations of Nonrenal Cancer	2520
Cutaneous Paraneoplastic Syndromes	2521
Neurologic Manifestations of Cancer	2525
Miscellaneous Paraneoplastic Syndromes	2531

48***Cancer of Unknown Primary Site 2537***

FRANK A. GRECO

JOHN D. HAINSWORTH

Poorly Differentiated Neoplasms of Unknown Primary Site 2538**Adenocarcinoma of Unknown Primary Site 2540****Squamous Carcinoma of Unknown Primary Site 2545****Poorly Differentiated Carcinoma (with or without Features
of Adenocarcinoma) of Unknown Primary Site 2546****Neuroendocrine Carcinoma of Unknown Primary Site 2552****Special Issues 2554****Conclusion: Future Trends 2556****49*****Peritoneal Carcinomatosis 2561***

DAVID L. BARTLETT

Pathophysiology 2561**Diagnosis 2562****Histologic Subtypes 2563****Treatment 2567****50*****Immunosuppression-Related Malignancies 2575*****SECTION 1 *AIDS-Related Malignancies 2575***

ROBERT YARCHOAN

RICHARD F. LITTLE

Kaposi's Sarcoma 2576**Acquired Immunodeficiency Syndrome–Associated
Lymphomas 2581****Primary Central Nervous System Lymphoma in Acquired
Immunodeficiency Syndrome 2587****Effect of Antiretroviral Therapy on Primary Central Nervous System
Lymphoma Incidence 2588****Hodgkin's Disease 2588****Anogenital Cancers in Human Immunodeficiency Virus
Infection 2589****Future Directions 2591****SECTION 2 *Transplantation-Related Malignancies 2597***

STANLEY R. RIDDELL

Immune Surveillance and Tumor Development 2597**Hematopoietic Stem Cell Transplant Recipients 2597****Organ Transplant Recipients 2602**

51

Oncologic Emergencies **2609**

SECTION 1 *Superior Vena Cava Syndrome* 2609

JOACHIM YAHALOM

Anatomy and Pathophysiology 2609

Etiology and Natural History 2609

Diagnostic Procedures 2611

Management 2612

Treatment 2613

Recommendations 2615

SECTION 2 *Spinal Cord Compression* 2617

BRIAN G. FULLER

JOHN D. HEISS

EDWARD H. OLDFIELD

Epidemiology 2617

Pathophysiology 2617

Clinical Presentation 2622

Diagnostic Evaluation 2623

Treatment 2624

Pediatric Spinal Cord Compression 2630

Conclusion 2630

SECTION 3 *Metabolic Emergencies* 2633

RAYMOND P. WARRELL, JR.

Hypercalcemia 2633

Treatment of Cancer-Related Hypercalcemia 2635

**General Approach to Treatment of
Hypercalcemia** 2638

Hyperuricemia 2639

Tumor Lysis Syndrome 2640

Lactic Acidosis 2640

Hypoglycemia 2641

Adrenal Failure 2642

SECTION 4 *Urologic Emergencies* 2645

McCLELLAN M. WALTHER

Urinary Tract Infection 2645

Cystitis 2645

Bladder Hemorrhage 2648

Urinary Obstruction 2649

Priapism 2650

Paraphimosis 2651

52

Treatment of Metastatic Cancer. 2655

SECTION 1 *Metastatic Brain Cancer 2655*

PATRICK Y. WEN
 PETER MCLAREN BLACK
 JAY S. LOEFFLER
 Incidence and Epidemiology 2655
 Method of Spread and Distribution 2655
 Clinical Manifestations 2656
 Diagnosis 2656
 Brain Metastases without a Known Primary Tumor 2657
 Management 2657
 Prognosis 2667

SECTION 2 *Metastatic Cancer to the Lung 2670*

JOE B. PUTNAM, JR.
 Historical Perspective 2670
 Identification of Pulmonary Metastases 2670
 Selection of Patients for Surgery 2672
 Preparation of the Patient for Metastasectomy 2673
 Surgical Incisions 2673
 Resection of Pulmonary Metastases 2674
 Survival Analysis 2674
 Results of Resection of Sarcomatous Pulmonary
 Metastases 2675
 Colorectal Neoplasms 2677
 Breast Carcinoma 2678
 Testicular Neoplasms 2679
 Gynecologic Neoplasms 2679
 Renal Cell Carcinoma 2680
 Melanoma 2680
 Squamous Cell Carcinoma 2680
 Wilms' Tumor 2680
 Metastasis or Primary Bronchogenic Carcinoma? 2681
 Recurrent Pulmonary Metastases 2681
 Extended Resection of Pulmonary Metastases 2681
 Prognostic Indicators 2683
 Resectability 2685
 Multivariate Analysis of Prognostic Indicators 2686
 Novel Treatment Strategies 2686

SECTION 3 *Metastatic Cancer to the Liver 2690*

H. RICHARD ALEXANDER
 CARMEN J. ALLEGRA
 THEODORE S. LAWRENCE
 Natural History of Liver Metastases 2690
 Imaging of Hepatic Metastases 2691
 Resection of Hepatic Metastases 2692
 Infusional Therapy for Hepatic Metastases 2697

Local Ablative Therapy	2702
Conclusions	2709

SECTION 4 *Metastatic Cancer to the Bone* **2713**

HOLLY K. BROWN
JOHN H. HEALEY

Presentation	2713
Pathogenesis	2714
Diagnostic Evaluation	2714
Treatment Goals	2715
Imaging of Bone Lesions	2716
Therapeutic Modalities	2717
Specific Anatomic Sites	2724

SECTION 5 *Malignant Pleural and Pericardial Effusions* **2729**

DAVID S. SCHRUMP
DAO M. NGUYEN

Malignant Pleural Effusion	2729
Malignant Pericardial Effusion	2736

SECTION 6 *Malignant Ascites* **2745**

FRANCESCO M. MARINCOLA
DOUGLAS J. SCHWARTZENTRUBER

Diagnosis and Workup	2745
Treatment of Malignant Ascites	2746

53

Hematopoietic Therapy **2753**

SECTION 1 *Transfusion Therapy* **2753**

PETER L. PERROTTA
EDWARD L. SNYDER

Blood Component Therapy	2754
Transfusion Reactions and Complications	2759
Transfusion-Transmitted Disease	2762
Use of Special Blood Products in Oncology	
Patients	2763
Apheresis	2764
Conclusions	2765

SECTION 2 *Autologous Stem Cell Transplantation* **2767**

DENNIS L. COOPER
STUART SEROPIAN

History	2767
Stem Cell Mobilization	2768
Inadequate Mobilization of Stem Cells	2770
Tumor Contamination	2771
Practical Considerations for the Potential High-Dose Therapy and Autologous Stem Cell Rescue Patient	2772

High-Dose Therapy Regimens: New Directions	2773
Late Toxicity: Myelodysplasia	2775
Future Directions	2775

SECTION 3	<i>Allogeneic Stem Cell Transplantation</i>	2779
	RICHARD W. CHILDS	
	Historical Perspective	2779
	Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies	2779
	Allogeneic Hematopoietic Stem Cell Transplantation for Nonmalignant Disorders	2779
	Preparative Regimens	2780
	Graft-versus-Leukemia Effect	2780
	Mechanisms	2782
	Complications of Allogeneic Hematopoietic Stem Cell Transplantation	2782
	Sources of Allogeneic Hematopoietic Stem Cells	2786
	Nonmyeloablative Allogeneic Stem Cell Transplantation	2788
	Results of Conventional Allogeneic Transplantation for Hematologic Malignancies	2791
	Future Prospects	2792

SECTION 4	<i>Hematopoietic Growth Factors</i>	2798
	JAMES D. GRIFFIN	
	Overview of Hematopoietic Growth Factors	2798
	Biologic Features of the Major Hematopoietic Growth Factors in Clinical Use	2800
	Clinical Applications of Hematopoietic Growth Factors in Cancer Therapy	2802
	Long-Term Effects of Growth Factor Administration	2809
	Conclusions	2809

54	<i>Infections in the Cancer Patient</i>	2815
	BRAHM H. SEGAL	
	THOMAS J. WALSH	
	STEVEN M. HOLLAND	
	Factors Predisposing to Infection in Patients with Cancer	2815
	Bacterial Pathogens in Cancer Patients	2820
	Fungal Infections	2825
	Viral Infections	2833
	Parasitic Infections	2839
	Evaluation and Management of Febrile Neutropenia	2841
	Manifestations and Therapy of Infections	2848
	Immune Augmentation Strategies	2858

55

Adverse Effects of Treatment 2869

SECTION 1 *Nausea and Vomiting* 2869

ANN M. BERGER
REBECCA A. CLARK-SNOW

Nature of the Problem 2869

Pathophysiology of Nausea and Vomiting 2869

Emetic Syndromes 2871

Control of Emesis and Patient Characteristics 2872

Antiemetic Agents 2873

Delayed Emesis 2875

Anticipatory Nausea and Vomiting 2875

Radiation-Induced Nausea and Vomiting 2876

Nausea and Vomiting Secondary to Comorbid
Conditions 2877

Cost and Benefit of Antiemetic Therapy 2877

SECTION 2 *Oral Complications* 2881

ANN M. BERGER
THOMAS J. KILROY

Direct Stomatotoxicity 2881

Pathophysiology of Mucositis 2882

Risk Factors 2882

Assessment of the Oral Mucosa 2883

Remedies for the Prevention and Treatment
of Mucositis 2883

Oral Complications in Radiotherapy 2889

Conclusion 2892

SECTION 3 *Pulmonary Toxicity* 2894

DIANE E. STOVER
ROBERT J. KANER

Radiation-Induced Pulmonary Toxicity 2894

Radiation-Related Bronchiolitis Obliterans
with Organizing Pneumonia 2896

Chemotherapy-Induced Pulmonary Toxicity 2897

SECTION 4 *Cardiac Toxicity* 2904

LAUREL J. STEINHERZ
JOACHIM YAHALOM

Chemotherapy 2904

Radiation-Induced Heart Disease 2912

Conclusion 2916

SECTION 5 *Hair Loss* 2922

CLAUDIA A. SEIPP

Head Covering 2922

Prevention of Alopecia 2923

SECTION 6	<i>Gonadal Dysfunction</i>	2923
	MARVIN L. MEISTRICH	
	RENA VASSILOPOULOU-SELLIN	
	LARRY I. LIPSHULTZ	
	Effects of Cytotoxic Agents on Adult Men	2924
	Effects of Cytotoxic Agents on Adult Women	2926
	Effects of Cytotoxic Agents on Children	2930
	Gonadal Dysfunction after Cranial Irradiation	2930
	Preservation of Fertility, Hormone Levels, and Sexual Function	2931
	Genetic Concerns	2934
	Counseling	2935

SECTION 7	<i>Second Cancers</i>	2939
	FLORA E. VAN LEEUWEN	
	LOIS B. TRAVIS	
	Methods to Assess Second Cancer Risk	2940
	Carcinogenicity of Individual Treatment Modalities	2941
	Risk of Second Malignancy in Patients with Selected Primary Cancers	2944
	Conclusion	2960

SECTION 8	<i>Miscellaneous Toxicities</i>	2964
	RAYMOND B. WEISS	
	Neurotoxicity	2964
	Nephrotoxicity	2968
	Hepatotoxicity	2970
	Hypersensitivity Reactions	2972
	Vascular Toxicity	2973

56

<i>Supportive Care and Quality of Life</i>	2977
---	-------------

SECTION 1	<i>Management of Cancer Pain</i>	2977
	KATHLEEN M. FOLEY	
	Epidemiology	2977
	Definition and Types of Cancer Pain	2979
	Types of Pain	2980
	Temporal Aspects of Pain	2980
	Intensity of Pain	2981
	Measurement of Pain	2981
	Classification of Patients with Cancer Pain	2984
	Group I: Acute Cancer-Related Pain	2984
	Group II: Chronic Cancer-Related Pain	2984
	Group III: Preexisting Chronic Pain and Cancer-Related Pain	2985
	Group IV: Patients with a History of Drug Addiction and Pain	2985
	Group V: Dying Patients with Pain	2986
	Common Pain Syndromes	2986
	Clinical Assessment of Pain	2986
	Management of Cancer Pain	2989

Analgesic Drug Therapy	2990
Classes of Drugs	2991
Principles of Opioid Drug Therapy	2994
Psychological Approaches	3001
Anesthetic and Neurosurgical Approaches	3002
Neurosurgical Approaches	3004
Physiatric Approaches	3007
Sedation in the Imminently Dying	3007
Algorithm for Cancer Pain Management	3009
Future Directions	3009

SECTION 2 *Nutritional Support* 3012

J. STANLEY SMITH
WILEY W. SOUBA

Clinical Manifestations of Cancer Cachexia	3012
Causes and Consequences of Cancer Cachexia	3013
Nutritional Support of the Cancer Patient	3017
Techniques of Providing Nutritional Support	3028
Nutrition Support for Cancer Patients and Health Care Reform	3030

SECTION 3 *Sexual Problems* 3032

PATRICIA A. GANZ
MARK S. LITWIN
BETH E. MEYEROWITZ

Sexual Health and Physiology	3032
Sexual Problems and Their Prevalence among the General Population	3034
Impact of Cancer and Its Treatment on Sexual Health	3035
Sexual Problems Associated with Specific Cancers	3040
Strategies for Assessment and Intervention	3044
Conclusions	3046

SECTION 4 *Genetic Counseling* 3049

ELLEN T. MATLOFF
ALLEN E. BALE

Who Is a Candidate for Cancer Genetic Counseling?	3050
Components of the Cancer Genetic Counseling Session	3051
Issues in Cancer Genetic Counseling	3054
Future Directions	3056

SECTION 5 *Psychological Issues* 3058

MARY JANE MASSIE
LISA CHERTKOV
ANDREW J. ROTH

Psychiatric Disorders in Cancer Patients	3058
Psychiatric Symptoms in Cancer Patients with Pain	3063
Unconventional Cancer Treatments	3063
Psychotherapeutic Interventions with Cancer Patients	3064
Survivor Issues	3064

SECTION 6	<i>Community Resources</i>	3066
	BONNIE A. INDECK	
	PHYLLIS M. SMITH	
	Initial Diagnosis of Cancer	3066
	Social Support Network	3066
	Emotional Support	3066
	Informational Support	3068
	Internet	3068
	Computer Groups	3069
	Instrumental Support	3069
	Trends Affecting Demand for Community Services	3071
	Survivorship	3072
	Appendix: Common Resources	3072
	Emotional Support	3074
	Financial Assistance	3074
	Home Health Care	3075

SECTION 7	<i>Specialized Care of the Terminally Ill</i>	3077
	FREDERICK A. FLATOW	
	SCOTT LONG	
	Overview of Hospice Care	3077
	Symptom Management	3079
	Conclusion	3086

57

<i>Rehabilitation of the Cancer Patient</i>	3089
--	-------------

LYNN GERBER
JEANNE HICKS
JAY SHAH

Cancer Rehabilitation Team	3090
Functional Assessment	3091
Common Functional Impairments in Oncology	3091
Tumor-Associated Myopathy	3093
Bone Replacement by Tumor	3094
Neuropathies and Plexopathies	3097
Lymphedema and Deep Venous Thrombosis	3098
Bowel and Bladder Disorders	3099
Psychosocial Aspects of Cancer Rehabilitation	3100
Rehabilitation and Management of Specific Tumors	3100
Conclusion	3109

58

<i>Advanced Practice Nurses and Physician Assistants in Oncology Care</i>	3111
--	-------------

M. TISH KNOBF
SUSAN ANDERSON

Physician Assistants	3111
Advanced Practice in Oncology Nursing	3112

59

Ethical Issues in Oncology and Clinical Trials. 3119

CHRISTOPHER DAUGHERTY
MARK SIEGLER

Ethical Issues in Cancer Clinical Care 3119

Ethical Issues in Cancer Clinical Trials 3126

Conclusions 3131

60

Information Systems in Oncology. 3135

SUSAN MOLLOY HUBBARD

National Cancer Institute's Information Services 3140

Conclusion 3146

61

Complementary, Alternative, and Unproven Methods of Cancer Treatment. 3147

JEFFREY D. WHITE

Definitions 3147

Phenomenology of Complementary and Alternative Medicine
in Cancer 3147

Reasons for Cancer Patient Use of Complementary and Alternative
Medicine Modalities 3148

Complementary and Alternative Medicine Therapies 3150

Supportive Care (Complementary Medicine) 3153

Complementary and Alternative Medicine Cancer Research 3154

Practical Issues in the Interface of Oncology and Complementary
and Alternative Medicine 3154

PART 4

NEWER APPROACHES IN CANCER TREATMENT

62

Genetic Therapy. 3161

SECTION 1 Gene Therapy 3161

PATRICK HWU

Methods of Gene Transfer 3161

Gene Marking Studies 3167

Genetic Modification of the Immune Response 3168

Modification of Tumors with Genes That Have Direct
Antitumor Effects 3173

Selective Replication of Virus in Tumors	3175
Introduction of Genes into Hematopoietic Stem Cells to Decrease Toxicity from Chemotherapy	3175
Antiangiogenic Gene Therapy	3176

SECTION 2	<i>Molecular Therapy</i>	3180
	ALBERT B. DEISSEROTH	
	AMANDA PSYRRI	
	DAVID J. AUSTIN	
	Strategies of New Drug Design	3181
	Approaches to Drug Design	3182
	Summary and Future Directions	3187

63

<i>Cancer Vaccines</i>	3189
------------------------	------

SECTION 1	<i>Preventive Cancer Vaccines</i>	3189
	DOUGLAS R. LOWY	
	JOHN T. SCHILLER	
	Infectious Agents and Cancer	3189
	Prophylactic Versus Therapeutic Vaccination	3191
	Hepatitis B Virus	3192
	Human Papillomavirus	3193
SECTION 2	<i>Therapeutic Cancer Vaccines</i>	3195
	NICHOLAS P. RESTIFO	
	MARIO SZNOL	
	WILLEM W. OVERWIJK	
	Immune Mechanisms Underlying Vaccine Function	3196
	Monitoring of Cancer Vaccine Trials	3198
	Anticancer Vaccine Approaches Derived from Autologous and Allogeneic Tumor Cells	3199
	Approaches Using Recombinant and Synthetic Anticancer Vaccines	3201
	Enhancing Vaccine-Induced Immune Responses	3210
	Future Challenges: Tumor Escape from Immune Recognition	3211
	Conclusion	3212

64

<i>Image-Guided Surgery</i>	3219
-----------------------------	------

	NICK BRYAN	
	STEVEN K. LIBUTTI	
	Medical Imaging Techniques	3219
	Image Guidance	3221
	Specific Applications of Image-Guided Surgery	3222
	Conclusions	3226

65

Proton Beam Radiation Therapy. 3229

IRA J. SPIRO
ALFRED R. SMITH
ANTHONY LOMAX
JAY S. LOEFFLER

Physical Aspects of Protons 3229
Proton Beam Radiation Treatment: Historical Note 3230
Clinical Results 3230
Design of Clinical Trials Using Proton Beams 3233
Conclusions and Future Directions 3234